Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center.
總部位於佛羅里達州的大麻公司Kaya Holdings Inc.，又名KAYS（OTCQB: KAYS）已獲得俄勒岡州衛生局頒發的經營迷幻藥服務中心的許可證。
Oregon is the only state in the US that has developed a licensing framework that allows for the administration of psilocybin in a safe and legal setting under the guidance of State Licensed Facilitators. KAYS through its Fifth Dimension Therapeutics, Inc. subsidiary, plans to operate The Sacred Mushroom, a full-service psychedelic treatment center that will allow clients to receive psilocybin treatment in a setting offering significant experience differentiators and concept innovations. The Sacred Mushroom expects to service its first guests within the next thirty days.
俄勒岡州是美國唯一一個制定了許可框架的州，該框架允許在州許可調解人的指導下，在安全和合法的環境中管理迷幻藥。KAYS計劃通過其子公司Fifth Dimension Therapeutics, Inc.運營The Sacred Mushroom，這是一家提供全方位服務的迷幻治療中心，將允許客戶在提供重要經驗差異化和概念創新的環境中接受迷幻藥治療。Sacred Mushroom預計將在未來三十天內爲第一批客人提供服務。
"The introduction of legal psilocybin treatments in Oregon marks the beginning of perhaps the most disruptive force in the mental health sector, transforming treatment protocol and redirecting resources," stated KAYS CEO Craig Frank. "Our distinctive guest experience model, the environment offered by the size and design of the facility and the dedication of our staff are designed to make The Sacred Mushroom the premier choice for anyone turning to psychedelics for relief or transformation. For these reasons, I believe KAYS is well positioned to become a leader in the 'delivery of care' of psychedelics."
KAYS首席執行官克雷格·弗蘭克表示：“俄勒岡州引入合法的迷幻藥治療可能標誌着心理健康領域最具顛覆性的力量的開始，它改變了治療方案並重新分配了資源。”“我們獨特的賓客體驗模式、設施規模和設計所提供的環境以及我們員工的奉獻精神旨在使The Sacred Mushroom成爲任何轉向迷幻藥來緩解或轉變的人的首選。出於這些原因，我相信KAYS完全有能力成爲迷幻藥'提供護理'的領導者。”
Cannabis and psychedelics sectors sometimes fuse, being similar in terms of both offering natural compounds to help treat various ailments. If you want to learn more about the future of the cannabis industry, join us at the Benzinga Cannabis Capital Conference this October in Chicago. Hear directly from key industry players and policymakers. Get your tickets now by following this link.
大麻和迷幻藥行業有時會融爲一體，兩者在提供天然化合物以幫助治療各種疾病方面相似。如果您想進一步了解大麻行業的未來，請加入我們今年10月在芝加哥舉行的Benzinga大麻資本會議。直接聽取主要行業參與者和政策制定者的意見。點擊此鏈接立即獲取門票。
Located on the top floor of the historic Falcon Building in downtown Portland and spread over approximately 11,000 square feet, The Sacred Mushroom will offer guests "room to roam,"unsurpassed comfort, optional private rooms, activity zones with yoga, listening stations, journaling chairs and art expression. There will also be a "sensation room," indoor garden and customized experience through its proprietary Synergy By Design "your setting, your way" program.
The Sacred Mushroom 位於波特蘭市中心歷史悠久的獵鷹大廈的頂層，佔地約 11,000 平方英尺，將爲客人提供 “漫遊空間”、無與倫比的舒適度、可選私人房間、帶瑜伽的活動區、聆聽站、日記椅和藝術表現形式。還將設有 “感覺室”、室內花園，並通過其專有的 “Synergy By Design” “你的設置，你的方式” 項目提供定製體驗。
Psilocybin, a naturally occurring compound found in "magic mushrooms," is one of an emerging class of psychedelic medicines that contain potent psychoactive chemicals that can affect human perception, emotions and other cognitive functions. Recent university medical studies have shown psilocybin treatment to be a potentially effective treatment path for people suffering from trauma, PTSD, depression, anxiety disorders, addictions and other hard-to-treat mental health conditions.
迷幻藥是一種天然存在於 “魔法蘑菇” 中的化合物，是新興的迷幻藥物之一，它含有強效的精神活性化學物質，可以影響人類的感知、情緒和其他認知功能。最近的大學醫學研究表明，對於患有創傷、創傷後應激障礙、抑鬱症、焦慮症、成癮和其他難以治療的心理健康狀況的人來說，迷幻藥治療是一種潛在的有效治療途徑。
Companies such as Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI), and Cybin (AMEX:CYBN) are engaged in developing synthetic versions of psilocybin and psilocin (the active ingredient in "magic mushrooms") to offer as alternative therapies for treatment-resistant mental health disorders. Delivery of these synthetic psilocybin options, when available, is expected to be administered at licensed psychedelic treatment centers such as The Sacred Mushroom.
Compass Pathways（納斯達克股票代碼：CMPS）、ATAI Life Sciences（納斯達克股票代碼：ATAI）和Cybin（美國證券交易所股票代碼：CYBN）等公司正在開發合成版本的迷幻藥和迷幻藥（“****” 中的活性成分），以作爲耐藥性心理健康障礙的替代療法。這些合成迷幻藥的交付如果可用，預計將在神聖蘑菇等獲得許可的迷幻治療中心進行治療。
Price Action
價格走勢
Kaya Holdings closed Wednesday market session 9.38% lower at $0.043 per share.
Kaya Holdings週三收盤下跌9.38％，至每股0.043美元。
Photo: Courtesy of KAYS
照片：由 KAYS 提供
譯文內容由第三人軟體翻譯。